Baidu
map

JCEM:胰岛素增敏剂可改善超重PCOS女性的内分泌和代谢状况

2020-06-05 MedSci原创 MedSci原创

对于超重的PCOS女性,二甲双胍联合GLP-1受体激动剂和二甲双胍联合TZD似乎在改善高雄激素血症方面优于单一疗法。二甲双胍联合TZDs在促进月经恢复方面可能特别有效。

近日,内分泌和代谢性疾病领域权威杂志Journal of Clinical Endocrinology & Metabolism上发表了一篇研究文章,该研究旨在评估胰岛素增敏剂对超重PCOS妇女月经频率、性激素和代谢参数的影响。

研究人员检索了多个数据库以获取RCT,检索时间从数据库成立到2019年9月,并使用多元随机效应方法进行网络荟萃分析。

该分析纳入了14项试验,共有619名妇女。与二甲双胍相比,二甲双胍+TZDs在月经恢复方面更具有优势(WMD为3.68,95%CI为1.65至8.20),二甲双胍+GLP-1受体激动剂在降低AND方面更有效(WMD为-2.53,95%CI为-3.96至- 1.09),二甲双胍+GLP-1受体激动剂(WMD为9.22,95%CI为5.46至12.98)和二甲双胍+TZDs(WMD为4.30,95%CI为0.78至7.82)在增加SHBG方面更有效,而TZDs在降低BMI方面效果较差(WMD为1.69,95%CI为0.72至2.66)。与GLP-1受体激动剂相比,二甲双胍+GLP-1受体激动剂与更高的SHBG(WMD为7.80,95%CI为4.75至10.85)、更低的FT(WMD为-1.77、95%CI为-3.25至-0.29)、更低的AND(WMD为-2.70,95%CI为-3.91至-1.50)和更低的FG(WMD为-0.41,95%CI为-0.73至-0.08)相关。

对于超重的PCOS女性,二甲双胍联合GLP-1受体激动剂和二甲双胍联合TZD似乎在改善高雄激素血症方面优于单一疗法。二甲双胍联合TZDs在促进月经恢复方面可能特别有效。与单独的GLP-1受体激动剂相比,二甲双胍联合GLP-1受体激动剂在改善空腹血糖方面具有额外的优势。TZD在降低BMI方面不如二甲双胍。

原始出处:

Chuan Xing,et al.Insulin Sensitizers for Improving the Endocrine and Metabolic Profile in Overweight Women with PCOS.JCEM.2020.https://doi.org/10.1210/clinem/dgaa337

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2063335, encodeId=3c262063335ba, content=<a href='/topic/show?id=14fb10264d7' target=_blank style='color:#2F92EE;'>#JCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10264, encryptionId=14fb10264d7, topicName=JCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Mon Jul 13 06:39:37 CST 2020, time=2020-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1777953, encodeId=f4ed1e779539d, content=<a href='/topic/show?id=eb9610265ed' target=_blank style='color:#2F92EE;'>#JCEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10265, encryptionId=eb9610265ed, topicName=JCEM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a4439169927, createdName=smallant2015, createdTime=Tue Jan 12 18:39:37 CST 2021, time=2021-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1750155, encodeId=a31f1e501551b, content=<a href='/topic/show?id=be7c8385345' target=_blank style='color:#2F92EE;'>#胰岛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83853, encryptionId=be7c8385345, topicName=胰岛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7a536274692, createdName=baoya, createdTime=Wed May 12 08:39:37 CST 2021, time=2021-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1809808, encodeId=51431809808b3, content=<a href='/topic/show?id=8a42838e9d6' target=_blank style='color:#2F92EE;'>#胰岛素增敏剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83879, encryptionId=8a42838e9d6, topicName=胰岛素增敏剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Thu Oct 22 21:39:37 CST 2020, time=2020-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1682612, encodeId=3fd516826125e, content=<a href='/topic/show?id=d4d031e8074' target=_blank style='color:#2F92EE;'>#分泌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31780, encryptionId=d4d031e8074, topicName=分泌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Mon Jun 29 09:39:37 CST 2020, time=2020-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=601571, encodeId=72e76015e172, content=二甲双胍联合GLP-1受体激动剂在PCOS中可能成为标准治疗<a href='/topic/show?id=3d2113865c8' target=_blank style='color:#2F92EE;'>#PCOS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=185, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13865, encryptionId=3d2113865c8, topicName=PCOS)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Sat Jun 06 10:03:13 CST 2020, time=2020-06-06, status=1, ipAttribution=)]
    2020-07-13 achengzhao
  2. [GetPortalCommentsPageByObjectIdResponse(id=2063335, encodeId=3c262063335ba, content=<a href='/topic/show?id=14fb10264d7' target=_blank style='color:#2F92EE;'>#JCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10264, encryptionId=14fb10264d7, topicName=JCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Mon Jul 13 06:39:37 CST 2020, time=2020-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1777953, encodeId=f4ed1e779539d, content=<a href='/topic/show?id=eb9610265ed' target=_blank style='color:#2F92EE;'>#JCEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10265, encryptionId=eb9610265ed, topicName=JCEM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a4439169927, createdName=smallant2015, createdTime=Tue Jan 12 18:39:37 CST 2021, time=2021-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1750155, encodeId=a31f1e501551b, content=<a href='/topic/show?id=be7c8385345' target=_blank style='color:#2F92EE;'>#胰岛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83853, encryptionId=be7c8385345, topicName=胰岛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7a536274692, createdName=baoya, createdTime=Wed May 12 08:39:37 CST 2021, time=2021-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1809808, encodeId=51431809808b3, content=<a href='/topic/show?id=8a42838e9d6' target=_blank style='color:#2F92EE;'>#胰岛素增敏剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83879, encryptionId=8a42838e9d6, topicName=胰岛素增敏剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Thu Oct 22 21:39:37 CST 2020, time=2020-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1682612, encodeId=3fd516826125e, content=<a href='/topic/show?id=d4d031e8074' target=_blank style='color:#2F92EE;'>#分泌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31780, encryptionId=d4d031e8074, topicName=分泌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Mon Jun 29 09:39:37 CST 2020, time=2020-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=601571, encodeId=72e76015e172, content=二甲双胍联合GLP-1受体激动剂在PCOS中可能成为标准治疗<a href='/topic/show?id=3d2113865c8' target=_blank style='color:#2F92EE;'>#PCOS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=185, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13865, encryptionId=3d2113865c8, topicName=PCOS)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Sat Jun 06 10:03:13 CST 2020, time=2020-06-06, status=1, ipAttribution=)]
    2021-01-12 smallant2015
  3. [GetPortalCommentsPageByObjectIdResponse(id=2063335, encodeId=3c262063335ba, content=<a href='/topic/show?id=14fb10264d7' target=_blank style='color:#2F92EE;'>#JCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10264, encryptionId=14fb10264d7, topicName=JCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Mon Jul 13 06:39:37 CST 2020, time=2020-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1777953, encodeId=f4ed1e779539d, content=<a href='/topic/show?id=eb9610265ed' target=_blank style='color:#2F92EE;'>#JCEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10265, encryptionId=eb9610265ed, topicName=JCEM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a4439169927, createdName=smallant2015, createdTime=Tue Jan 12 18:39:37 CST 2021, time=2021-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1750155, encodeId=a31f1e501551b, content=<a href='/topic/show?id=be7c8385345' target=_blank style='color:#2F92EE;'>#胰岛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83853, encryptionId=be7c8385345, topicName=胰岛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7a536274692, createdName=baoya, createdTime=Wed May 12 08:39:37 CST 2021, time=2021-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1809808, encodeId=51431809808b3, content=<a href='/topic/show?id=8a42838e9d6' target=_blank style='color:#2F92EE;'>#胰岛素增敏剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83879, encryptionId=8a42838e9d6, topicName=胰岛素增敏剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Thu Oct 22 21:39:37 CST 2020, time=2020-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1682612, encodeId=3fd516826125e, content=<a href='/topic/show?id=d4d031e8074' target=_blank style='color:#2F92EE;'>#分泌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31780, encryptionId=d4d031e8074, topicName=分泌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Mon Jun 29 09:39:37 CST 2020, time=2020-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=601571, encodeId=72e76015e172, content=二甲双胍联合GLP-1受体激动剂在PCOS中可能成为标准治疗<a href='/topic/show?id=3d2113865c8' target=_blank style='color:#2F92EE;'>#PCOS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=185, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13865, encryptionId=3d2113865c8, topicName=PCOS)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Sat Jun 06 10:03:13 CST 2020, time=2020-06-06, status=1, ipAttribution=)]
    2021-05-12 baoya
  4. [GetPortalCommentsPageByObjectIdResponse(id=2063335, encodeId=3c262063335ba, content=<a href='/topic/show?id=14fb10264d7' target=_blank style='color:#2F92EE;'>#JCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10264, encryptionId=14fb10264d7, topicName=JCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Mon Jul 13 06:39:37 CST 2020, time=2020-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1777953, encodeId=f4ed1e779539d, content=<a href='/topic/show?id=eb9610265ed' target=_blank style='color:#2F92EE;'>#JCEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10265, encryptionId=eb9610265ed, topicName=JCEM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a4439169927, createdName=smallant2015, createdTime=Tue Jan 12 18:39:37 CST 2021, time=2021-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1750155, encodeId=a31f1e501551b, content=<a href='/topic/show?id=be7c8385345' target=_blank style='color:#2F92EE;'>#胰岛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83853, encryptionId=be7c8385345, topicName=胰岛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7a536274692, createdName=baoya, createdTime=Wed May 12 08:39:37 CST 2021, time=2021-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1809808, encodeId=51431809808b3, content=<a href='/topic/show?id=8a42838e9d6' target=_blank style='color:#2F92EE;'>#胰岛素增敏剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83879, encryptionId=8a42838e9d6, topicName=胰岛素增敏剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Thu Oct 22 21:39:37 CST 2020, time=2020-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1682612, encodeId=3fd516826125e, content=<a href='/topic/show?id=d4d031e8074' target=_blank style='color:#2F92EE;'>#分泌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31780, encryptionId=d4d031e8074, topicName=分泌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Mon Jun 29 09:39:37 CST 2020, time=2020-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=601571, encodeId=72e76015e172, content=二甲双胍联合GLP-1受体激动剂在PCOS中可能成为标准治疗<a href='/topic/show?id=3d2113865c8' target=_blank style='color:#2F92EE;'>#PCOS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=185, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13865, encryptionId=3d2113865c8, topicName=PCOS)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Sat Jun 06 10:03:13 CST 2020, time=2020-06-06, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2063335, encodeId=3c262063335ba, content=<a href='/topic/show?id=14fb10264d7' target=_blank style='color:#2F92EE;'>#JCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10264, encryptionId=14fb10264d7, topicName=JCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Mon Jul 13 06:39:37 CST 2020, time=2020-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1777953, encodeId=f4ed1e779539d, content=<a href='/topic/show?id=eb9610265ed' target=_blank style='color:#2F92EE;'>#JCEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10265, encryptionId=eb9610265ed, topicName=JCEM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a4439169927, createdName=smallant2015, createdTime=Tue Jan 12 18:39:37 CST 2021, time=2021-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1750155, encodeId=a31f1e501551b, content=<a href='/topic/show?id=be7c8385345' target=_blank style='color:#2F92EE;'>#胰岛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83853, encryptionId=be7c8385345, topicName=胰岛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7a536274692, createdName=baoya, createdTime=Wed May 12 08:39:37 CST 2021, time=2021-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1809808, encodeId=51431809808b3, content=<a href='/topic/show?id=8a42838e9d6' target=_blank style='color:#2F92EE;'>#胰岛素增敏剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83879, encryptionId=8a42838e9d6, topicName=胰岛素增敏剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Thu Oct 22 21:39:37 CST 2020, time=2020-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1682612, encodeId=3fd516826125e, content=<a href='/topic/show?id=d4d031e8074' target=_blank style='color:#2F92EE;'>#分泌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31780, encryptionId=d4d031e8074, topicName=分泌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Mon Jun 29 09:39:37 CST 2020, time=2020-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=601571, encodeId=72e76015e172, content=二甲双胍联合GLP-1受体激动剂在PCOS中可能成为标准治疗<a href='/topic/show?id=3d2113865c8' target=_blank style='color:#2F92EE;'>#PCOS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=185, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13865, encryptionId=3d2113865c8, topicName=PCOS)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Sat Jun 06 10:03:13 CST 2020, time=2020-06-06, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=2063335, encodeId=3c262063335ba, content=<a href='/topic/show?id=14fb10264d7' target=_blank style='color:#2F92EE;'>#JCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10264, encryptionId=14fb10264d7, topicName=JCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Mon Jul 13 06:39:37 CST 2020, time=2020-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1777953, encodeId=f4ed1e779539d, content=<a href='/topic/show?id=eb9610265ed' target=_blank style='color:#2F92EE;'>#JCEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10265, encryptionId=eb9610265ed, topicName=JCEM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a4439169927, createdName=smallant2015, createdTime=Tue Jan 12 18:39:37 CST 2021, time=2021-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1750155, encodeId=a31f1e501551b, content=<a href='/topic/show?id=be7c8385345' target=_blank style='color:#2F92EE;'>#胰岛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83853, encryptionId=be7c8385345, topicName=胰岛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7a536274692, createdName=baoya, createdTime=Wed May 12 08:39:37 CST 2021, time=2021-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1809808, encodeId=51431809808b3, content=<a href='/topic/show?id=8a42838e9d6' target=_blank style='color:#2F92EE;'>#胰岛素增敏剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83879, encryptionId=8a42838e9d6, topicName=胰岛素增敏剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Thu Oct 22 21:39:37 CST 2020, time=2020-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1682612, encodeId=3fd516826125e, content=<a href='/topic/show?id=d4d031e8074' target=_blank style='color:#2F92EE;'>#分泌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31780, encryptionId=d4d031e8074, topicName=分泌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Mon Jun 29 09:39:37 CST 2020, time=2020-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=601571, encodeId=72e76015e172, content=二甲双胍联合GLP-1受体激动剂在PCOS中可能成为标准治疗<a href='/topic/show?id=3d2113865c8' target=_blank style='color:#2F92EE;'>#PCOS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=185, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13865, encryptionId=3d2113865c8, topicName=PCOS)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Sat Jun 06 10:03:13 CST 2020, time=2020-06-06, status=1, ipAttribution=)]
    2020-06-06 lovetcm

    二甲双胍联合GLP-1受体激动剂在PCOS中可能成为标准治疗#PCOS#

    0

相关资讯

J Clin Oncol:个体化内分泌辅助治疗让绝经前HR+/HER2-乳腺癌患者**获益

临床对TEXT和SOFT研究已经非常熟悉,激素受体阳性、HER2阳性乳腺癌患者根据临床病理特征进行复发风险分层,不同人群5年乳腺癌复发风险的绝对改善程度具有很大差别。近期《临床肿瘤学杂志》(The Journal of Clinical Oncology)发布对两个研究数据进行进一步分析结果,在HR+/HER2-乳腺癌患者中评估不同亚组患者的远处复发风险。

乳腺癌病例:辅助内分泌原发耐药患者晚期一线化疗后氟维司群维持治疗的重要性

乳腺癌是女性恶性肿瘤发病率最高的疾病,是威胁女性“健康”的杀手,乳腺癌防治受到广泛的关注。激素受体阳性乳腺癌占乳腺癌中70% ~ 80%,术后患者需要接受5 ~ 10年的内分泌治疗,多数患者能够获得较好的预后,但即使如此,仍有部分患者出现复发转移。本文分享一例绝经前激素阳性乳腺癌患者的诊疗历程,探讨这类患者的诊疗思路。

Cell :修复与癌变|呼吸道神经内分泌细胞的干细胞功能

在生物发育过程中,分化往往被认为是不可逆的过程。生物为应对部分组织的快速更新,往往在发育过程中选择保留一部分低分化的干细胞,如骨髓和皮肤中存在的造血干细胞和表皮干细胞。但对于更新缓慢的大多数其他组织,典型意义上的干细胞往往难觅踪迹。相反,这类组织经常选择利用部分分化程度较高并具有特定生理功能的细胞来完成组织修复或更新工作,而这部分仅在特定条件下具有部分干细胞特性和转分化(Transdifferen

Lancet Oncol:绝经后HR+/HER2-转移性乳腺癌一线或二线治疗——内分泌为基础治疗较化疗更优

多项重要的随机临床研究已经证实,内分泌联合靶向治疗用于绝经后HR+/HER2-患者一线或二线治疗,可以带来显着的获益。鉴于此,目前所有主要的国际指南均推荐内分泌为基础的序贯方案应该作为优选方案,除非患者合并内脏危象。然而真实世界数据显示,一线化疗仍然非常常见,即使患者没有合并内脏危象。近日发布在《柳叶刀·肿瘤》(Lancet Oncology)的一项大型网络荟萃分析,系统性评估对比了内分泌治疗和化

年终盘点:2019年内分泌领域重磅级亮点研究成果丨梅斯医述评

2019年科学家们在内分泌研究领域发表了很多重磅级的研究,本文中小M就对2019年该领域发表的亮点研究进行整理,分享给大家!

Preprint:青春痘?黄褐斑?皮肤状况之谜,肠道菌群和内分泌一起回答你!

导言:几十年来,人们已经清楚皮肤状况受到人体内分泌周期的影响,巧用激素能够缓解某些症状。而最近,继脑肠轴、肠激素轴之后,肠皮轴的研究正如火如荼地开展。结合肠道菌群、内分泌和皮肤菌群三者相互制衡的关系,

Baidu
map
Baidu
map
Baidu
map